Eureka Therapeutics

Eureka to start phase I ET190L1-ARTEMIS T cell therapy trial

Monday, November 27, 2017

Eureka Therapeutics, a clinical stage biotechnology company focused on improving the safety profile of T cell therapies and developing novel T cell therapies for the treatment of solid tumors, announced FDA allowance of its investigational new drug (IND) application and authorization to commence a phase I clinical trial for ET190L1-ARTEMIS T cells in Relapsed and Refractory CD19+ Non-Hodgkin Lymphoma (NHL), including Chronic Lymphocytic Leukemia (CLL). Eureka expects to enroll the first patient in this trial in the first quarter of 2018.

[Read More]

Juno partners Memorial Sloan Kettering and Eureka Therapeutics

Tuesday, August 9, 2016

Juno Therapeutics, a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer, has entered into an exclusive license agreement with Memorial Sloan-Kettering Cancer Center (MSK) and Eureka Therapeutics for a novel, fully-human binding domain targeting B-cell maturation antigen (BCMA), along with binding domains against two additional undisclosed multiple myeloma targets to be used for the potential development and commercialization of chimeric antigen receptor (CAR) cell therapies for patients with multiple myeloma.

[Read More]